FDA approves Bracco Diagnostics' ProHance (gadoteridol) Injection, 279.3 mg/mL, for paediatric patients younger than two years

Bracco Diagnostics

23 December 2020 - Bracco Diagnostics today announced that the U.S. FDA has approved ProHance (gadoteridol 279.3 mg/mL injection) for intravenous use with magnetic resonance imaging in paediatric patients under two years old, including term neonates, to visualise areas with disrupted blood brain barrier and/or abnormal vascularity throughout the brain, spine and associated tissues.

ProHance was previously approved for this use in patient populations over the age of two.

Read Bracco Diagnostics press release

Michael Wonder

Posted by:

Michael Wonder